<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: This study determines the long-term efficacy of the <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi>, enalapril, in reducing the progression of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> to clinical <z:mp ids='MP_0002871'>albuminuria</z:mp> in normotensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: There were 103 normotensive type 2 diabetic patients with persistent albumin excretion rate (AER) 20-200 micrograms/min and <z:mpath ids='MPATH_458'>normal</z:mpath> renal function followed for 5 years in a prospective randomized single-blind placebo-controlled trial </plain></SENT>
<SENT sid="2" pm="."><plain>AER, blood pressure, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, and HbA1 were measured very 3-4 months and glomerular filtration rate (GFR), renal plasma flow (RPF), and urinary <z:chebi fb="20" ids="16199">urea</z:chebi> every 12 months </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: In the patients treated with enalapril, AER decreased from 55 +/- 33 to 20 +/- 59 micrograms/min (geometric mean +/- SD), whereas in the placebo group, AER increased from 53 +/- 31 to 85 +/- 90 micrograms/min after 5 years </plain></SENT>
<SENT sid="4" pm="."><plain>Within 5 years, 7.7% (4/52) of enalapril-treated subjects and 23.5% (12/51) of placebo-treated subjects progressed to clinical <z:mp ids='MP_0002871'>albuminuria</z:mp> defined as AER &gt; 200 micrograms/min and at least 34% above baseline (risk reduction = 66.7%, P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>AER increased at an annual rate of 12.3% (95% CI 9.8-14.9) in the placebo group, while it declined by 16.7% (95% CI -18.3 to -15.2) in the enalapril group (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, 8 of the 12 placebo-treated patients had evidence of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The rest of the parameters remained practically unchanged in the two groups </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: After 5 years of therapy with enalapril, compared with placebo, normotensive subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> experienced significantly less progression of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> to clinical <z:mp ids='MP_0002871'>albuminuria</z:mp>, reduced AER, and preserved GFR </plain></SENT>
</text></document>